Skip to content
OpenCapital
Get started

Trevi Therapeutics, Inc. TRVI Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value at other companies

CHE
ChemedCHE
85.8-25.1%
HTF
Heartflow, Inc. Common StockHTFL
15.9+124%
KEE
Keel Infrastructure Corp. Common StockKEEL
$0.72-35.7%
Belden logo
BeldenBDC
$39.44+80.5%
KEE
Keel Infrastructure Corp. Common StockKEEL
$1.08+4.9%
Boston Beer logo
Boston BeerSAM
$343.91-10.0%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K—
Free cash flow-$16.8M—

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0×0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.

The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value?
Trevi Therapeutics, Inc. (TRVI) reported share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value of $4.01 in Q4 2025.
How has Trevi Therapeutics, Inc.'s share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value changed year-over-year?
Trevi Therapeutics, Inc.'s share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value increased by 84.8% year-over-year, from $2.17 to $4.01.
What does share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value mean?
The average fair value of stock options granted to employees as of the date of the grant, calculated using valuation models like Black-Scholes. This metric is a key indicator of the economic cost of equity-based compensation provided to the workforce.